{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:32:03Z","timestamp":1794457923544,"version":"4.9.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102217","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:16:05Z","timestamp":1790061365000},"page":"102217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights"],"prefix":"10.1016","volume":"67","author":[{"given":"Grace M.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Reyes-Baez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhalak","family":"Dholakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2010.07.001","article-title":"Long-term outcome and natural history of uterine adenosarcomas","volume":"119","author":"Arend","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102217_bb0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2014.10.022","article-title":"Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence","volume":"135","author":"Carroll","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0090-8258(03)00258-0","article-title":"Low-grade endometrial stromal sarcoma: hormonal aspects","volume":"90","author":"Chu","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102217_bb0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0046-8177(90)90198-E","article-title":"Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature","volume":"21","author":"Clement","year":"1990","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102217_bb0035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ygyno.2010.12.363","article-title":"Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma","volume":"121","author":"Dos Santos","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2026.102217_bb0045","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1634\/theoncologist.2016-0079","article-title":"Sarcomas associated with genetic Cancer predisposition syndromes: a review","volume":"21","author":"Farid","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0050","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12957-022-02781-1","article-title":"Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma","volume":"20","author":"Feng","year":"2022","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2021.02.016","article-title":"Phase 2 study of anastrozole in patients with estrogen receptor\/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: the PARAGON trial (ANZGOG 0903)","volume":"161","author":"Friedlander","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.06.011","article-title":"The management of patients with uterine sarcoma: a debated clinical challenge","volume":"65","author":"Gadducci","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.gore.2026.102217_bb0065","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine Leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.gore.2026.102217_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejogrb.2023.06.016","article-title":"Uterine sarcomas: a critical review of the literature","volume":"287","author":"Giannini","year":"2023","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"7","key":"10.1016\/j.gore.2026.102217_bb0080","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/1078-0432.CCR-23-2250","article-title":"Phase II study of Eribulin plus Pembrolizumab in metastatic soft-tissue sarcomas: clinical outcomes and biological correlates","volume":"30","author":"Haddox","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.gore.2026.102217_bb0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/CCO.0b013e32833aafef","article-title":"Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas","volume":"22","author":"Hensley","year":"2010","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102217_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.gore.2026.102217_bb0095","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0100","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.211658","article-title":"MRI evaluation of uterine masses for risk of leiomyosarcoma: a consensus statement","volume":"306","author":"Hindman","year":"2023","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.gore.2026.102217_bb0105","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","article-title":"Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database","volume":"26","author":"Hosh","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102217_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13023-016-0400-8","article-title":"JAZF1\/SUZ12 gene fusion in endometrial stromal sarcomas","volume":"11","author":"Hrzenjak","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.gore.2026.102217_bb0115","article-title":"Treatment patterns and outcomes for primary uterine leiomyosarcoma with synchronous isolated lung metastases: a National Cancer Database study of primary resection and metastasectomy","volume":"51","author":"Istl","year":"2024","journal-title":"Gynecol Oncol Rep."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2011.04.003","article-title":"Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas","volume":"122","author":"Jaakkola","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102217_bb0125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.gore.2026.102217_bb0130","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-22-0518","article-title":"Phase II clinical trial of Eribulin-gemcitabine combination therapy in previously treated patients with advanced Liposarcoma or Leiomyosarcoma","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.gore.2026.102217_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100044","article-title":"High-grade endometrial stromal sarcomas with YWHAE::NUTM2 gene fusion exhibit recurrent CDKN2A alterations and absence of p16 staining is a poor prognostic marker","volume":"36","author":"Kommoss","year":"2023","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.gore.2026.102217_bb0140","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.annonc.2021.04.014","article-title":"A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French sarcoma group trial","volume":"32","author":"Le Cesne","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ygyno.2012.02.014","article-title":"Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis","volume":"125","author":"Leitao","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102217_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040921","article-title":"New insights into hormonal therapies in uterine sarcomas","volume":"14","author":"Maccaroni","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.gore.2026.102217_bb0155","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00404-023-07057-x","article-title":"Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study","volume":"308","author":"Macuks","year":"2023","journal-title":"Arch. Gynecol. Obstet."},{"issue":"12","key":"10.1016\/j.gore.2026.102217_bb0160","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1158\/1078-0432.CCR-21-3951","article-title":"Circulating tumor DNA is associated with response and survival in patients with advanced Leiomyosarcoma","volume":"28","author":"Madanat-Harjuoja","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0165","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","article-title":"Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity","volume":"160","author":"Matsuzaki","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.gore.2026.102217_bb0170","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41379-022-01160-1","article-title":"Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors","volume":"35","author":"Momeni Boroujeni","year":"2022","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAP.0000000000000478","article-title":"Risk stratification of uterine smooth muscle tumors: the role of morphology, immunohistochemistry, and molecular testing","volume":"32","author":"Momeni-Boroujeni","year":"2025","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(25)00654-0","article-title":"Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial","volume":"27","author":"Monga","year":"2026","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-026-15618-x","article-title":"Risk factors for recurrent cases of early-stage uterine sarcoma after complete surgical resection","volume":"26","author":"Nagao","year":"2026","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gore.2026.102217_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2021.101589","article-title":"Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database","volume":"38","author":"Nasioudis","year":"2021","journal-title":"Surg. Oncol."},{"issue":"15","key":"10.1016\/j.gore.2026.102217_bb0195","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.gore.2026.102217_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.10.028","article-title":"A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: a unicancer French sarcoma group study (LMS03 study)","volume":"125","author":"Pautier","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.gore.2026.102217_bb0205","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2026.102217_bb0210","article-title":"Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors","volume":"9","author":"Rao","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102217_bb0215","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","article-title":"ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas","volume":"34","author":"Ray-Coquard","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.gore.2026.102217_bb0220","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer group study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gore.2026.102217_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2024.10.008","article-title":"Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: a retrospective study","volume":"191","author":"Saab","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaoncol.2020.6564","article-title":"Efficacy of Pazopanib with or without gemcitabine in patients with anthracycline- and\/or Ifosfamide-refractory soft tissue sarcoma: final results of the PAPAGEMO phase 2 randomized clinical trial","volume":"7","author":"Schmoll","year":"2021","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.gore.2026.102217_bb0235","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","article-title":"Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes","volume":"12","author":"Sch\u00f6ffski","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0240","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.05.036","article-title":"Low-grade and high-grade endometrial stromal sarcoma: a National Cancer Database study","volume":"146","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102217_bb0245","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.gore.2026.102217_bb0250","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1007\/s00261-021-03263-w","article-title":"MR imaging of uterine sarcomas: a comprehensive review with radiologic-pathologic correlation","volume":"46","author":"Sousa","year":"2021","journal-title":"Abdom Radiol (NY)."},{"issue":"2","key":"10.1016\/j.gore.2026.102217_bb0255","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ygyno.2018.03.008","article-title":"Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: a multicenter review","volume":"149","author":"Stewart","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.gore.2026.102217_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17244012","article-title":"The evolving molecular landscape of uterine mesenchymal tumors: diagnostic and therapeutic implications","volume":"17","author":"Sun","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"5 Pt 1","key":"10.1016\/j.gore.2026.102217_bb0265","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0029-7844(96)00003-8","article-title":"Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the gynecologic oncology group","volume":"87","author":"Sutton","year":"1996","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.gore.2026.102217_bb0270","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2026.102217_bb0275","article-title":"Development of an algorithm to differentiate uterine sarcoma from fibroids using MRI and LDH levels","volume":"13","author":"Suzuki","year":"2023","journal-title":"Diagnostics (Basel)."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2012.12.036","article-title":"Management of uterine adenosarcomas with and without sarcomatous overgrowth","volume":"129","author":"Tanner","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.gore.2026.102217_bb0285","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0290","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2021.05.003","article-title":"Uterine carcinosarcomas: from pathology to practice","volume":"162","author":"Toboni","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41392-025-02278-9","article-title":"Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab","volume":"10","author":"Toulmonde","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9829","key":"10.1016\/j.gore.2026.102217_bb0300","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.gore.2026.102217_bb0305","article-title":"Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature","volume":"35","author":"Wang","year":"2021","journal-title":"Gynecol Oncol Rep."},{"issue":"11","key":"10.1016\/j.gore.2026.102217_bb0310","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","article-title":"Association of tamoxifen and uterine sarcoma","volume":"20","author":"Wickerham","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2026.102217_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2024.06.026","article-title":"Uterine cancer incidence trends and 5-year relative survival by race\/ethnicity and histology among women under 50 years","volume":"231","author":"Wijayabahu","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.gore.2026.102217_bb0320","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-Centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102217_bb0325","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.gore.2026.102217_bb0330","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1158\/1078-0432.CCR-20-4315","article-title":"Molecular biomarkers of response to Eribulin in patients with Leiomyosarcoma","volume":"27","author":"Wozniak","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0335","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2014.206","article-title":"Use of electric power Morcellation and prevalence of underlying Cancer in women who undergo myomectomy","volume":"1","author":"Wright","year":"2015","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102217_bb0340","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e58","article-title":"Differentiation of uterine fibroids and sarcomas by MRI and serum LDH levels: a multicenter study of the KAMOGAWA study","volume":"36","author":"Yamanishi","year":"2025","journal-title":"J. Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.gore.2026.102217_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/cells13131106","article-title":"Comprehensive review of uterine Leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy","volume":"13","author":"Yang","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.gore.2026.102217_bb0350","doi-asserted-by":"crossref","unstructured":"Zammarrelli WA, 3rd, Greenman M, Rios-Doria E, Miller K, Broach V, Mueller JJ, et al. Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. Gynecol. Oncol. 2022;165(2):287\u201392.","DOI":"10.1016\/j.ygyno.2022.02.012"},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0355","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12885-020-07003-z","article-title":"Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gore.2026.102217_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010157","article-title":"Feasibility of longitudinal ctDNA assessment in patients with uterine and extra-uterine leiomyosarcoma","volume":"15","author":"Zhou","year":"2022","journal-title":"Cancers (Basel)."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:16:02Z","timestamp":1794456962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"alternative-id":["S2352578926001979"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102217","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102217"}}